B-cell malignancies

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The mature B-cell neoplasms include numerous subtypes of B-cell leukemias and lymphomas (BCL), as well as plasma cell neoplasms. BCL represent 80-90 % of mature lymphoid leukemias and non-Hodgkin lymphomas (NHL) in the Western world. BCL subtypes include numerous distinct diseases, with different biologies, natural histories, morphologic characteristics, immunophenotypes, genetic features, prognoses, and responses to therapy. BCL also include the majority of immunodeficiency-associated lymphomas. Accurate subclassification of BCL has been a challenge for pathologists, resulting in early application of new techniques in molecular analysis to improve diagnostic accuracy. Today, the molecular features of BCL are used to aid in rendering an accurate diagnosis, to predict prognosis, to help determine optimal therapy, and to assess for minimal residual disease (MRD) after therapy. The molecular abnormalities in BCL have commonly been evaluated for clinical purposes, including those occurring in genes coding for antigen receptor (AgR) molecules and those occurring in oncogenes and tumor suppressor genes. This chapter will discuss current molecular testing methods for BCL, as well as some of the newer methods being developed for BCL.

Original languageEnglish (US)
Title of host publicationMolecular Pathology in Clinical Practice
Subtitle of host publicationSecond Edition
PublisherSpringer International Publishing
Pages579-602
Number of pages24
ISBN (Electronic)9783319196749
ISBN (Print)9783319196732
DOIs
StatePublished - Jan 1 2016

Fingerprint

B-Cell Leukemia
B-Cell Lymphoma
B-Lymphocytes
Neoplasms
Plasma Cell Neoplasms
Lymphoid Leukemia
Western World
Antigen Receptors
Residual Neoplasm
Tumor Suppressor Genes
Natural History
Oncogenes
Non-Hodgkin's Lymphoma
Lymphoma
Therapeutics

Keywords

  • B-cell leukemia
  • B-cell lymphoma
  • Immunodeficiency-associated lymphoma
  • Immunoglobulin receptor gene rearrangement
  • Molecular testing
  • Non-Hodgkin lymphoma
  • Oncogenes
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dunlap, J., Fan, G., Leeborg, N., & Braziel, R. (2016). B-cell malignancies. In Molecular Pathology in Clinical Practice: Second Edition (pp. 579-602). Springer International Publishing. https://doi.org/10.1007/978-3-319-19674-9_42

B-cell malignancies. / Dunlap, Jennifer; Fan, Guang; Leeborg, Nicky; Braziel, Rita.

Molecular Pathology in Clinical Practice: Second Edition. Springer International Publishing, 2016. p. 579-602.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dunlap, J, Fan, G, Leeborg, N & Braziel, R 2016, B-cell malignancies. in Molecular Pathology in Clinical Practice: Second Edition. Springer International Publishing, pp. 579-602. https://doi.org/10.1007/978-3-319-19674-9_42
Dunlap J, Fan G, Leeborg N, Braziel R. B-cell malignancies. In Molecular Pathology in Clinical Practice: Second Edition. Springer International Publishing. 2016. p. 579-602 https://doi.org/10.1007/978-3-319-19674-9_42
Dunlap, Jennifer ; Fan, Guang ; Leeborg, Nicky ; Braziel, Rita. / B-cell malignancies. Molecular Pathology in Clinical Practice: Second Edition. Springer International Publishing, 2016. pp. 579-602
@inbook{75b05fe6f9b541fe921cec187e9e8d85,
title = "B-cell malignancies",
abstract = "The mature B-cell neoplasms include numerous subtypes of B-cell leukemias and lymphomas (BCL), as well as plasma cell neoplasms. BCL represent 80-90 {\%} of mature lymphoid leukemias and non-Hodgkin lymphomas (NHL) in the Western world. BCL subtypes include numerous distinct diseases, with different biologies, natural histories, morphologic characteristics, immunophenotypes, genetic features, prognoses, and responses to therapy. BCL also include the majority of immunodeficiency-associated lymphomas. Accurate subclassification of BCL has been a challenge for pathologists, resulting in early application of new techniques in molecular analysis to improve diagnostic accuracy. Today, the molecular features of BCL are used to aid in rendering an accurate diagnosis, to predict prognosis, to help determine optimal therapy, and to assess for minimal residual disease (MRD) after therapy. The molecular abnormalities in BCL have commonly been evaluated for clinical purposes, including those occurring in genes coding for antigen receptor (AgR) molecules and those occurring in oncogenes and tumor suppressor genes. This chapter will discuss current molecular testing methods for BCL, as well as some of the newer methods being developed for BCL.",
keywords = "B-cell leukemia, B-cell lymphoma, Immunodeficiency-associated lymphoma, Immunoglobulin receptor gene rearrangement, Molecular testing, Non-Hodgkin lymphoma, Oncogenes, Tumor suppressor genes",
author = "Jennifer Dunlap and Guang Fan and Nicky Leeborg and Rita Braziel",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-19674-9_42",
language = "English (US)",
isbn = "9783319196732",
pages = "579--602",
booktitle = "Molecular Pathology in Clinical Practice",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - B-cell malignancies

AU - Dunlap, Jennifer

AU - Fan, Guang

AU - Leeborg, Nicky

AU - Braziel, Rita

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The mature B-cell neoplasms include numerous subtypes of B-cell leukemias and lymphomas (BCL), as well as plasma cell neoplasms. BCL represent 80-90 % of mature lymphoid leukemias and non-Hodgkin lymphomas (NHL) in the Western world. BCL subtypes include numerous distinct diseases, with different biologies, natural histories, morphologic characteristics, immunophenotypes, genetic features, prognoses, and responses to therapy. BCL also include the majority of immunodeficiency-associated lymphomas. Accurate subclassification of BCL has been a challenge for pathologists, resulting in early application of new techniques in molecular analysis to improve diagnostic accuracy. Today, the molecular features of BCL are used to aid in rendering an accurate diagnosis, to predict prognosis, to help determine optimal therapy, and to assess for minimal residual disease (MRD) after therapy. The molecular abnormalities in BCL have commonly been evaluated for clinical purposes, including those occurring in genes coding for antigen receptor (AgR) molecules and those occurring in oncogenes and tumor suppressor genes. This chapter will discuss current molecular testing methods for BCL, as well as some of the newer methods being developed for BCL.

AB - The mature B-cell neoplasms include numerous subtypes of B-cell leukemias and lymphomas (BCL), as well as plasma cell neoplasms. BCL represent 80-90 % of mature lymphoid leukemias and non-Hodgkin lymphomas (NHL) in the Western world. BCL subtypes include numerous distinct diseases, with different biologies, natural histories, morphologic characteristics, immunophenotypes, genetic features, prognoses, and responses to therapy. BCL also include the majority of immunodeficiency-associated lymphomas. Accurate subclassification of BCL has been a challenge for pathologists, resulting in early application of new techniques in molecular analysis to improve diagnostic accuracy. Today, the molecular features of BCL are used to aid in rendering an accurate diagnosis, to predict prognosis, to help determine optimal therapy, and to assess for minimal residual disease (MRD) after therapy. The molecular abnormalities in BCL have commonly been evaluated for clinical purposes, including those occurring in genes coding for antigen receptor (AgR) molecules and those occurring in oncogenes and tumor suppressor genes. This chapter will discuss current molecular testing methods for BCL, as well as some of the newer methods being developed for BCL.

KW - B-cell leukemia

KW - B-cell lymphoma

KW - Immunodeficiency-associated lymphoma

KW - Immunoglobulin receptor gene rearrangement

KW - Molecular testing

KW - Non-Hodgkin lymphoma

KW - Oncogenes

KW - Tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=85027515128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027515128&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-19674-9_42

DO - 10.1007/978-3-319-19674-9_42

M3 - Chapter

AN - SCOPUS:85027515128

SN - 9783319196732

SP - 579

EP - 602

BT - Molecular Pathology in Clinical Practice

PB - Springer International Publishing

ER -